1. Home
  2. ABR vs NGNE Comparison

ABR vs NGNE Comparison

Compare ABR & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbor Realty Trust

ABR

Arbor Realty Trust

N/A

Current Price

$1.27

Market Cap

809.7M

Sector

Real Estate

ML Signal

N/A

Logo Neurogene Inc.

NGNE

Neurogene Inc.

N/A

Current Price

$24.23

Market Cap

744.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ABR
NGNE
Founded
2003
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
809.7M
744.9M
IPO Year
2003
2014

Fundamental Metrics

Financial Performance
Metric
ABR
NGNE
Price
$1.27
$24.23
Analyst Decision
Hold
Strong Buy
Analyst Count
5
10
Target Price
$2.25
★ $77.63
AVG Volume (30 Days)
★ 9.1M
303.2K
Earning Date
10-30-2026
11-09-2026
Dividend Yield
★ 72.31%
N/A
EPS Growth
N/A
★ 0.93
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.28
$15.93
52 Week High
$9.30
$43.66

Technical Indicators

Market Signals
Indicator
ABR
NGNE
Relative Strength Index (RSI) 14.22 41.94
Support Level N/A $19.47
Resistance Level $5.38 $28.47
Average True Range (ATR) 0.15 2.71
MACD -0.05 -0.06
Stochastic Oscillator 0.28 15.12

Price Performance

Historical Comparison
ABR
NGNE

About ABR Arbor Realty Trust

Arbor Realty Trust Inc is a specialized real estate finance company. It invests in a diversified portfolio of structured finance assets in the multifamily, SFR, and commercial real estate markets, consisting of bridge and mezzanine loans, including junior participating interests in first mortgages, preferred, and direct equity. In addition, it may also directly acquire real property and invest in real estate-related notes and certain mortgage-related securities. The company has two business segments, Structured Business and Agency Business. It generates a majority of its revenue from the Structured Business Segment.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: